Neuland FY26 Net Profit Rises 40%; Dividend ₹34/Share
Neuland Laboratories reported a 40% increase in FY26 net profit to ₹363.1 crore, driven by a 37.1% rise in revenue to ₹2,053.1 crore. Q4FY26 saw significant growth with PAT rising 666.3% to ₹212.5 crore. The Board recommended a final dividend of ₹34 per share and approved capacity expansion at Unit 1.
*this image is generated using AI for illustrative purposes only.
Neuland Laboratories reported a strong financial performance for the year ended March 31, 2026, with consolidated net profit rising 40% to ₹363.1 crore from ₹259.4 crore in the prior year. Revenue from operations grew to ₹2,053.1 crore compared to ₹1,497.3 crore in FY25. The Board of Directors, at their meeting held on May 12, 2026, approved the audited standalone and consolidated financial results under Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
Commenting on the performance, Saharsh Davuluri, Chief Executive Officer and Managing Director, stated: "We are pleased with the fact that we have ended FY26 on a strong note in line with our original expectations. There is good business visibility in the short to medium term anchored by commercial and near-commercial molecules. Our focus on execution discipline, customer satisfaction, and protection of business fundamentals is central to ensuring this phase of growth. At the same time, we are laying the groundwork for growth beyond this horizon. Key elements of this foundation are the investments in Peptide Manufacturing as well as the new R&D Centre, which are proceeding according to plan. Our Business Development strategy is aligned to the investments and is focused on bringing in the right kind of projects that support high quality, sustainable growth."
Consolidated Financial Performance
The company reported significant growth across key financial metrics on a consolidated basis for FY26. Total consolidated income reached ₹2,053.1 crore compared to ₹1,497.3 crore in FY25. Profit before tax (excluding exceptional items) stood at ₹488.9 crore for FY26 versus ₹269.9 crore in FY25. The prior year's profit before tax of ₹346.3 crore included an exceptional item of ₹76.4 crore arising from the transfer of an investment property in Nanakramguda, Hyderabad.
The following table summarises the consolidated financial results:
| Metric: | FY26 (Audited) | FY25 (Audited) |
|---|---|---|
| Revenue from Operations: | ₹2,02,298.54 lakhs | ₹1,47,683.73 lakhs |
| Other Income: | ₹3,016.62 lakhs | ₹2,050.93 lakhs |
| Total Income: | ₹2,05,315.16 lakhs | ₹1,49,734.66 lakhs |
| Total Expenses: | ₹1,56,417.45 lakhs | ₹1,22,742.12 lakhs |
| Profit Before Exceptional Item & Tax: | ₹48,897.71 lakhs | ₹26,992.54 lakhs |
| Profit Before Tax: | ₹48,897.71 lakhs | ₹34,632.90 lakhs |
| Net Profit: | ₹36,399.84 lakhs | ₹26,010.81 lakhs |
| Total Comprehensive Income: | ₹36,506.25 lakhs | ₹26,006.33 lakhs |
| Basic & Diluted EPS (₹10 each): | ₹283.71 | ₹202.74 |
Quarterly Performance Highlights
Neuland Laboratories delivered a sharp acceleration in profitability during Q4FY26. Total Income for the quarter stood at ₹788.7 crore, up 134.9% year-on-year from ₹335.8 crore in Q4FY25. Q4 EBITDA stood at ₹319.4 crore versus ₹58.2 crore in the prior-year quarter, with EBITDA margin expanding to 40.5% from 17.3% in Q4FY25. Working capital days of sale stood at 137 days in Q4FY26 as against 145 days in Q3FY26, mainly on account of a decrease in inventory.
The following table presents the quarterly financial summary:
| Particulars (₹ crore): | Q4FY26 | Q4FY25 | YoY (%) | Q3FY26 | QoQ (%) |
|---|---|---|---|---|---|
| Total Income: | 788.7 | 335.8 | 134.90% | 447.8 | 76.10% |
| EBITDA: | 319.4 | 58.2 | 448.60% | 85.0 | 275.80% |
| EBITDA Margin: | 40.50% | 17.30% | 2316 bps | 19.00% | 2151 bps |
| Profit Before Tax: | 287.0 | 39.0 | 636.60% | 54.3 | 428.90% |
| PBT Margin: | 36.40% | 11.60% | 2479 bps | 12.10% | 2430 bps |
| Profit After Tax: | 212.5 | 27.7 | 666.30% | 40.4 | 425.80% |
| PAT Margin: | 26.90% | 8.30% | 1869 bps | 9.00% | 1789 bps |
| EPS (₹): | 165.6 | 21.6 | 666.30% | 31.5 | 425.80% |
Final Dividend and AGM
The Board of Directors recommended a final dividend of ₹34/- (340%) per equity share of ₹10 each for the financial year 2025-26, subject to shareholder approval. The dividend will be paid on or after five days from the date of declaration at the 42nd Annual General Meeting (AGM), which has been scheduled for Tuesday, August 4, 2026. The record date for determining shareholders eligible to receive the final dividend has been fixed as July 24, 2026.
Source: None/Company/INE794A01010/1ba40a77d673415b.pdf
Historical Stock Returns for Neuland Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.12% | +5.45% | +13.72% | -1.11% | +35.28% | +577.06% |
How will the 120.5 KL capacity expansion at Unit 1 position Neuland to handle potential large-scale peptide manufacturing orders, and could this trigger further capacity additions at other units within the next 2-3 years?
Given the sharp revenue concentration in USA/North America and Europe, how might evolving US drug pricing policies or potential tariffs on Indian API imports impact Neuland's export-driven revenue model in FY27?
With 10 molecules in Phase 3 clinical trials in the CMS pipeline, what is the realistic timeline and revenue potential if even a subset of these progress to commercialization over the next 3-5 years?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
